Palvella Therapeutics (PVLA) Common Equity (2013 - 2026)

Palvella Therapeutics (PVLA) has 14 years of Common Equity data on file, last reported at $232.3 million in Q1 2026.

• Common Equity for Q1 2026 came in at $232.3 million, up 318.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $232.3 million (up 318.0% YoY), and the FY2025 annual result was $28.0 million, down 55.3% from the prior year.
• Common Equity climbed to $232.3 million in Q1 2026 per PVLA's latest filing, from $28.0 million in the prior quarter.
• Over five years, Common Equity peaked at $317.5 million in Q3 2022 and troughed at -$93.8 million in Q4 2022.
• A 5-year average of $32.5 million and a median of $38.7 million in 2025 frame the typical range for Common Equity.
• The sharpest annual moves came in 2022 and 2024: Common Equity jumped 489.55% in 2022, then plunged 597.3% in 2024.
• A 5-year view of Common Equity shows it stood at -$93.8 million in 2022, then grew by 20.57% to -$74.5 million in 2023, then jumped by 184.06% to $62.6 million in 2024, then sank by 55.3% to $28.0 million in 2025, then soared by 730.19% to $232.3 million in 2026.
• Business Quant data shows PVLA's Common Equity at $232.3 million in Q1 2026, $28.0 million in Q4 2025, and $38.7 million in Q3 2025.